News >

Studies Stopped for Daratumumab/Checkpoint Inhibitor Combos in NSCLC, Myeloma

Silas Inman @silasinman
Published: Tuesday, May 29, 2018

Jan van de Winkel, PhD

Jan van de Winkel, PhD
Two separate early-phase clinical trials exploring daratumumab (Darzalex) in combination with either a PD-1 inhibitor for multiple myeloma or a PD-L1 inhibitor for non–small cell lung cancer (NSCLC) were terminated following a planned interim analysis, according to a statement from Genmab, the company codeveloping daratumumab with Janssen.

Another phase II study was exploring durvalumab (Imfinzi) and daratumumab for multiple myeloma; however, this trial was terminated shortly following the mandated partial hold in September 2017. This single-arm trial, however, was stopped due to a lack of efficacy, according to its clinicaltrials.gov listing (NCT03000452).
FDA Alerts Healthcare Professionals and Oncology Clinical Investigators about Two Clinical Trials on Hold Evaluating KEYTRUDA® (pembrolizumab) in Patients with Multiple Myeloma. https://www.fda.gov/Drugs/DrugSafety/ucm574305.htm. Accessed August 31, 2017.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x